The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Seliverstov E.I.

Lobastov K.V.

Ilyukhin E.A.

Apkhanova T.V.

Akhmetzyanov R.V.

Akhtyamov I.F.

Barinov V.E.

Bakhmetiev A.S.

Belov M.V.

Bobrov S.A.

Bozhkova S.A.

Bredikhin R.A.

Bulatov V.L.

Vavilova T.V.

Vardanyan A.V.

Vorobiev N.A.

Gavrilov E.K.

Gavrilov S.G.

Golovina V.I.

Gorin A.S.

Dzhenina O.V.

Dianov S.V.

Efremova O.I.

Zhukovets V.V.

Zamyatin M.N.

Ignatiev I.A.

Kalinin R.E.

Kamaev A.A.

Kaplunov O.A.

Karimova G.N.

Karpenko A.A.

Kasimova A.R.

Katelnitskaya O.V.

Katelnitsky I.I.

Katorkin S.E.

Knyazev R.I.

Konchugova T.V.

Kopenkin S.S.

Koshevoy A.P.

Kravtsov P.F.

Krylov A.Yu.

Kulchitskaya D.B.

Laberko L.A.

Lebedev I.S.

Malanin D.A.

Matyushkin A.V.

Mzhavanadze N.D.

Moiseev S.V.

Mushtin N.E.

Nikolaeva M.G.

Pelevin A.V.

Petrikov A.S.

Piradov M.A.

Pikhanova Zh.M.

Poddubnaya I.V.

Porembskaya O.Ya.

Potapov M.P.

Pyregov A.V.

Rachin A.P.

Rogachevsky O.V.

Ryabinkina Yu.V.

Sapelkin S.V.

Sonkin I.N.

Soroka V.V.

Sushkov S.A.

Schastlivtsev I.V.

Tikhilov R.M.

Tryakin A.A.

Fokin A.A.

Khoronenko V.E.

Khruslov M.V.

Tsaturyan A.B.

Tsed A.N.

Cherkashin M.A.

Chechulova A.V.

Chuiko S.G.

Shimanko A.I.

Shmakov R.G.

Yavelov I.S.

Yashkin M.N.

Kirienko A.I.

Zolotukhin I.A.

Stoyko Yu.M.

Suchkov I.A.

Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus

Authors:

Seliverstov E.I., Lobastov K.V., Ilyukhin E.A., Apkhanova T.V., Akhmetzyanov R.V., Akhtyamov I.F., Barinov V.E., Bakhmetiev A.S., Belov M.V., Bobrov S.A., Bozhkova S.A., Bredikhin R.A., Bulatov V.L., Vavilova T.V., Vardanyan A.V., Vorobiev N.A., Gavrilov E.K., Gavrilov S.G., Golovina V.I., Gorin A.S., Dzhenina O.V., Dianov S.V., Efremova O.I., Zhukovets V.V., Zamyatin M.N., Ignatiev I.A., Kalinin R.E., Kamaev A.A., Kaplunov O.A., Karimova G.N., Karpenko A.A., Kasimova A.R., Katelnitskaya O.V., Katelnitsky I.I., Katorkin S.E., Knyazev R.I., Konchugova T.V., Kopenkin S.S., Koshevoy A.P., Kravtsov P.F., Krylov A.Yu., Kulchitskaya D.B., Laberko L.A., Lebedev I.S., Malanin D.A., Matyushkin A.V., Mzhavanadze N.D., Moiseev S.V., Mushtin N.E., Nikolaeva M.G., Pelevin A.V., Petrikov A.S., Piradov M.A., Pikhanova Zh.M., Poddubnaya I.V., Porembskaya O.Ya., Potapov M.P., Pyregov A.V., Rachin A.P., Rogachevsky O.V., Ryabinkina Yu.V., Sapelkin S.V., Sonkin I.N., Soroka V.V., Sushkov S.A., Schastlivtsev I.V., Tikhilov R.M., Tryakin A.A., Fokin A.A., Khoronenko V.E., Khruslov M.V., Tsaturyan A.B., Tsed A.N., Cherkashin M.A., Chechulova A.V., Chuiko S.G., Shimanko A.I., Shmakov R.G., Yavelov I.S., Yashkin M.N., Kirienko A.I., Zolotukhin I.A., Stoyko Yu.M., Suchkov I.A.

More about the authors

Journal: Journal of Venous Disorders. 2023;17(3): 152‑296

Read: 30637 times


To cite this article:

Seliverstov EI, Lobastov KV, Ilyukhin EA, et al. Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus. Journal of Venous Disorders. 2023;17(3):152‑296. (In Russ.)
https://doi.org/10.17116/flebo202317031152

Recommended articles:
Signs of high embo­lic risk in iliocaval floating thro­mbi. Piro­gov Russian Journal of Surgery. 2025;(3):56-62
Changes in diagnosis-related group payment model in the Russian Fede­ration in 2025. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):18-30
Approaches to the digi­tization of clinical guidelines. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):39-47
Modern approach to the treatment of acute iliofemoral thro­mbosis. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):293-299
Unre­solved questions of recu­rrent implantation failure. Russian Journal of Human Reproduction. 2025;(3):42-47
Thro­mboembolic complications in the postpartum period. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):102-107

References:

  1. Bokeriya LA, Zatevahin II, Kirienko AI. Rossijskie klinicheskie rekomendacii po diagnostike, lecheniyu i profilaktike venoznyh tromboembolicheskih oslozhnenij (VTEO). Flebologiya. 2015;2(4):2. (In Russ.).
  2. Perrin M, Eklof B, Maleti O. The vein glossary. J Vasc Surg Venous Lymphat Disord. 2018;6(5):11-217. 
  3. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34-45. 
  4. Diaz JA, et al. Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application. J Thromb Haemost. 2019;17(4):699-707. 
  5. von Brühl M-L, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835. 
  6. Kumar NG, et al. Fibrinolytic activity of endothelial cells from different venous beds. J Surg Res. 2015;194(1):297-303. 
  7. Gupta N, Zhao Y-Y, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. 
  8. Xu J, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15(11):1318-1321.
  9. Wakefield TW, Myers DD, Henke PK. Role of selectins and fibrinolysis in VTE. Thromb Res. 2009;123(suppl):35-40. 
  10. Laurance S, et al. Gas6 Promotes Inflammatory (CCR2hiCX3CR1lo) Monocyte Recruitment in Venous Thrombosis. Arterioscler Thromb Vasc Biol. 2017;37(7):1315-1322.
  11. Swystun LL, Liaw PC. The role of leukocytes in thrombosis. Blood. 2016; 128(6):753-762. 
  12. Barranco-Medina S, et al. Histone H4 promotes prothrombin autoactivation. J Biol Chem. 2013;288(50):35749-35757.
  13. Fuchs TA, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci. 2010;107(36):15880-15885.
  14. Ammollo CT, et al. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost. 2011;9(9):1795-1803.
  15. Ward CM, et al. Binding of the von Willebrand factor A1 domain to histone. Thromb Res. 1997;86(6):469-477. 
  16. Semeraro F, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011;118(7):1952-1961.
  17. Okano M, et al. In vivo Imaging of Venous Thrombus and Pulmonary Embolism Using Novel Murine Venous Thromboembolism Model. JACC. 2020;5(4):344-356. 
  18. Cooley BC. In vivo fluorescence imaging of large-vessel thrombosis in mice. Arterioscler Thromb Vasc Biol. 2011;31(6):1351-1356.
  19. Shaya SA, et al. Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. J Thromb Haemost. 2016;14(1):143-152. 
  20. Shaya SA, et al. Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. Thromb Haemost. 2019;119(6):992-999. 
  21. Deroo S, Deatrick KB, Henke PK. The vessel wall: A forgotten player in post thrombotic syndrome. Thromb. 2010;104(4):681-692. 
  22. Modarai B, et al. The role of neovascularisation in the resolution of venous thrombus. Thromb Haemost. 2005;93(5):801-809. 
  23. Fineschi V, et al. Histological age determination of venous thrombosis: a neglected forensic task in fatal pulmonary thrombo-embolism. Forensic Sci Int. 2009;186(1-3):22-28. 
  24. Lee Y-U, et al. Histological and biomechanical changes in a mouse model of venous thrombus remodeling. Biorheology. 2015;52(3):235-245. 
  25. Comerota AJ, et al. A histological and functional description of the tissue causing chronic postthrombotic venous obstruction. Thromb Res. 2015; 135(5):882-887. 
  26. Aguilera CM, et al. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res. 2003;58(3):679-688. 
  27. Nicklas JM, Gordon AE, Henke PK. Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms. Int J Mol Sci. 2020;21(6):2080.
  28. Adelman B, et al. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985;65(1):32-40. 
  29. Singh I, et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation. 2003;107(6):869-875. 
  30. Suzuki Y, et al. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. Blood. 2011;118(11):3182-3185.
  31. Baldwin JF, et al. The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. J Vasc Surg. 2012;56(4):1089-1097.
  32. Weitz JI, Leslie B, Hirsh J. α2-Antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest. 1993;91(4):1343-1350.
  33. Urano T, Castellino FJ, Suzuki Y. Regulation of plasminogen activation on cell surfaces and fibrin. J Thromb Haemost. 2018;16(8):1487-1497.
  34. Fields GB. Interstitial collagen catabolism. J Biol Chem. 2013;288(13):8785-8793.
  35. Mosevoll KA, et al. Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. Thromb Res. 2015;136(1):30-39. 
  36. Nguyen KP, et al. Matrix Metalloproteinase 9 (MMP-9) Regulates Vein Wall Biomechanics in Murine Thrombus Resolution. PLoS One. 2015;10(9): e0139145.
  37. Nosaka M, et al. Time-dependent appearance of intrathrombus neutrophils and macrophages in a stasis-induced deep vein thrombosis model and its application to thrombus age determination. Int J Legal Med. 2009;123(3): 235-240. 
  38. Kirsch R, et al. Fibrinogen is degraded and internalized during incubation with neutrophils, and fibrinogen products localize to electron lucent vesicles. Biochem J. 2002;364(Pt 2):403-412. 
  39. McGuinness CL, et al. Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost. 2001;85(6):1018-1024.
  40. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871-882. 
  41. Chang C-F, et al. Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage. J Clin Invest. 2018;128(2):607-624. 
  42. Dewyer NA, et al. Divergent effects of Tlr9 deletion in experimental late venous thrombosis resolution and vein wall injury. Thromb Haemos. 2015; 114(5):1028-1037.
  43. Fleetwood AJ, et al. Urokinase plasminogen activator is a central regulator of macrophage three-dimensional invasion, matrix degradation, and adhesion. J Immunol. 2014;192(8):3540-3547.
  44. Meznarich J, et al. Urokinase Plasminogen Activator Induces Pro-Fibrotic/M2 Phenotype in Murine Cardiac Macrophages. PLoS One. 2013; 8(3):e57837.
  45. Sheng J, et al. M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death Dis. 2018;9(7):755. 
  46. Lin F, Wang N, Zhang T. The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life. 2012;64(9):717-723. 
  47. Piera-Velazquez S, Jimenez SA. Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases. Physiol Rev. 2019;99(2):1281-1324.
  48. Privratsky JR, Newman DK, Newman PJ. PECAM-1: conflicts of interest in inflammation. Life Sci. 2010;87(3-4):69-82. 
  49. Lertkiatmongkol P, et al. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr Opin Hematol. 2016;23(3):253-259. 
  50. Li W-D, Li X-Q. Endothelial progenitor cells accelerate the resolution of deep vein thrombosis. Vascul Pharmacol. 2016;83:10-16. 
  51. Podor TJ, et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem. 2002;277(9):7529-7539.
  52. Diaz JA, et al. P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor. Arterioscler Thromb Vasc Biol. 2015;35(4):829-837. 
  53. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3-14. 
  54. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12(8):464-474. 
  55. Spencer FA, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722-727. 
  56. Silverstein MD, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585-593. 
  57. Naess IA, et al. Incidence and mortality of venous thrombosis: a population-based study. Thromb Haemost. 2007;5(4):692-699. 
  58. Roach REJ, et al. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment: reply. Thromb Thrombolysis. 2015;13(5):886-887. 
  59. Kane EV, et al. A population-based study of venous thrombosis in pregnancy in Scotland 1980-2005. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):223-229. 
  60. Heit JA, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697-706. 
  61. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128(9):737-740. 
  62. Zakai NA, McClure LA, Judd SE. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation. 2014;129(14):1502-1509.
  63. Cheuk BLY, Cheung GCY, Cheng SWK. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg. 2004;91(4):424-428. 
  64. Hooper WC, et al. Venous thromboembolism hospitalizations among American Indians and Alaska Natives. Thromb Res. 2002;108(5-6):273-278. 
  65. Khan F, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363.
  66. Schulman S, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. Thromb Thrombolysis. 2006;4(4):734-742. 
  67. van Dongen CJJ, et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med. 2003;163(11):1285-1293.
  68. Franchini M, Mannucci PM. ABO blood group and thrombotic vascular disease. Thromb Haemos. 2014;112(6):1103-1109.
  69. Bank I, et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004;164(17):1932-1937.
  70. Olaf M, Cooney R. Deep Venous Thrombosis. Emerg Med Clin North Am. 2017;35(4):743-770. 
  71. Tomchenko AI, i dr. Gruppy krovi AB0 i tromboz glubokih ven nizhnih konechnostej u pacientov pozhilogo i starcheskogo vozrasta. Flebologiya. 2021;15(1):33-38. (In Russ.).
  72. Chechulova AV, i dr. Ocenka gen-gennyh vzaimodejstvij ryada faktorov plazmennogo zvena gemostaza u pacientov s rannim debyutom venoznyh tromboembolicheskih oslozhnenij. Flebologiya. 2021;15(1):50-56. (In Russ.).
  73. Gavrilov EK, i dr. Vozmozhnoe znachenie nasledstvennyh trombofilij v vozniknovenii i oslozhnennom techenii idiopaticheskih ostryh venoznyh trombozov nizhnih konechnostej. Flebologiya. 2020;14(2):83-88. (In Russ.).
  74. van Stralen KJ, et al. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol. 2008;28(10):1872-1877.
  75. Meissner MH. Epidemiology and risk factors of acute venous thrombosis. Handbook of Venous and Lymphatic Disorders. CRC Press; 2017;107-119. 
  76. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? Thromb Thrombolysis. 2011;9(2): 257-266. 
  77. de Bastos M, et al. Combined oral contraceptives: venous thrombosis. Cochrane database Syst Rev. 2014;3:CD010813.
  78. Roderick P. Epidemiology of Venous Thromboembolism. Clin Risk. 1997; 3(3):69-74. 
  79. Ay C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377-5382.
  80. Sciascia S, et al. Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. Clin Mol Allergy. 2016;14(1):6. 
  81. Gris J-C, et al. Thrombosis and paroxysmal nocturnal haemoglobinuria. Thromb Updat. 2021;5:100074.
  82. Mazzolai L, et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular fu. Eur J Prev Cardiol. 2022;29(8):1248-1263.
  83. Kearon C, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. Thromb Thrombolysis. 2016;14(7):1480-1483.
  84. Konstantinides SV, Meyer G, Galié N. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J. 2019;54(3).
  85. Kakkos S, Gohel M, Baekgaard N. Editor’s Choice ‒ European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc. 2021;61(1):9-82. 
  86. Stevens SM, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6): 545-608. 
  87. Prins MH, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018;2(7):788-796. 
  88. Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496-520. 
  89. Iorio A, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710-1716.
  90. Alhabouni S, et al. PP88. Lower Extremity Occlusive vs Non-occlusive DVT and the Risk of Pulmonary Embolism. J Vasc Surg. 2009;49(5):S40. 
  91. Pacouret G. Free-Floating Thrombus and Embolic Risk in Patients With Angiographically Confirmed Proximal Deep Venous Thrombosis. A Prospective Study. Arch Intern Med. 1997;157(3):305. 
  92. Ortel TL, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738.
  93. Robert-Ebadi H, Righini M. Should we diagnose and treat distal deep vein thrombosis? Hematol Am Soc Hematol. 2017;2017(1):231-236. 
  94. Krut’ko VS, Potejko PI, Hodosh EM. Naruzhnye simptomy u bol’nyh s tromboemboliej legochnoj arterii. Medicina neotlozhnyh sostoyanij. 2013; 2(49):49-56. (In Russ.).
  95. Nebylicin YuS, Sushkov SA. Diagnostika tromboza glubokih ven nizhnih konechnostej. Novosti hirurgii. 2007;15(3):45-55. (In Russ.).
  96. Bojko VV, Krivorot’ko IV. Strategiya hirurgicheskogo lecheniya mestnorasprostranennyh opuholej malogo taza s primeneniem evisceracij. Soobshchenie 3. Rak pryamoj kishki, matki, yaichnikov, predstatel’noj zhelezy, teratoidnye opuholi malogo taza. Mezhdunarodnyj medicinskij zhurnal. Іnstitut problem krіobіologії і krіomedicini NAN Ukraїni. 2008. (In Russ.).
  97. Greer IA. Clinical Practice. Pregnancy Complicated by Venous Thrombosis. N Engl J Med. 2015;373(6):540-547. 
  98. Chan W-S, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ. 2010;182(7):657-660. 
  99. Wells PS. Integrated strategies for the diagnosis of venous thromboembolism. Thromb Thrombolysis. 2007;5(suppl 1):41-50. 
  100. Wells PS, et al. Does this patient have deep vein thrombosis? JAMA. 2006; 295(2):199-207. 
  101. Páramo JA, Bounameaux H, Levi M. Scores and Algorithms in Haemostasis and Thrombosis. Madrid: Grupo Acción Médica; 2014.
  102. Geersing GJ, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ. 2014;348:g1340.
  103. Wells PS, Anderson DR, Rodger M. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemos. 2000;83(03):416-420. 
  104. Shen J-H, et al. Comparison of the Wells score with the revised Geneva score for assessing suspected pulmonary embolism: a systematic review and meta-analysis. Thromb Thrombolysis. 2016;41(3):482-492. 
  105. Le Gal G, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern. 2006;144(3):165-171. 
  106. Tritschler T, et al. Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA. 2018;320(15):1583-1594.
  107. Cuker A, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392.
  108. Bernardi E, Camporese G. Diagnosis of deep-vein thrombosis. Thromb Res. 2018;163:201-206. 
  109. Michiels JJ, et al. Duplex ultrasound, clinical score, thrombotic risk, and D-dimer testing for evidence based diagnosis and management of deep vein thrombosis and alternative diagnoses in the primary care setting and outpatient ward. Int Angiol. 2014;33(1):1-19. 
  110. Streiff MB, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Thromb Thrombolysis. 2016;41(1):32-67. 
  111. Ye F, et al. Venothromboembolic signs and medical eponyms: Part II. Thromb Res. 2019;182:205-213. 
  112. Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: The value of clinical assessment in the diagnosis of deep venous thrombosis. Ann Intern Med. 2005;143(2):129-139. 
  113. Michiels J.J, et al. A critical appraisal of non-invasive diagnosis and exclusion of deep vein thrombosis and pulmonary embolism in outpatients with suspected deep vein thrombosis or pulmonary embolism: how many tests do we need? Int Angiol. 2005;24(1):27-39. 
  114. Sartori M, et al. The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis. Thromb Thrombolysis. 2012;10(11):2264-2269.
  115. Al-Khafaji R.A., Schierbeck L. Deep Venous Thrombosis in a Patient with a Moderate Pretest Probability and a Negative D-Dimer Test: A Review of the Diagnostic Algorithms J Blood Med. 2020;11:173-184. 
  116. Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. Thromb Thrombolysis. 2013;11(3):412-422. 
  117. Le Gal G, Righini M. Controversies in the diagnosis of venous thromboembolism. Thromb Thrombolysis. 2015;13(suppl 1):259-265. 
  118. Stone J, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017;7(suppl 3):276-284. 
  119. Hargett CW, Tapson VF. Clinical probability and D-dimer testing: how should we use them in clinical practice? Semin Respir Crit Care Med. 2008; 29(1):15-24. 
  120. Hirsh J, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):141-159. 
  121. Hong J, et al. Updated recommendations for the treatment of venous thromboembolism. Blood Res. Korean Society of Hematology. 2021;56(1):6-16. 
  122. Garcia DA, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):24-43. 
  123. DeWald TA, Washam JB, Becker RC. Anticoagulants: Pharmacokinetics, Mechanisms of Action, and Indications. Neurosurg Clin N Am. 2018; 29(4):503-515. 
  124. Guyatt GH, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):7-47. 
  125. Chen A, Stecker E, Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. J Am Heart Assoc. 2020;9(13): e017559.
  126. Guyatt GH, Akl EA, Crowther M. Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):7. 
  127. Wu T, et al. The effect of anti‐Xa monitoring on the safety and efficacy of low‐molecular‐weight heparin anticoagulation therapy: A systematic review and meta‐analysis. J Clin Pharm Ther. 2020;45(4):602-608. 
  128. Hutt Centeno E, Militello M, Gomes MP. Anti-Xa assays: What is their role today in antithrombotic therapy? Cleve Clin J Med. 2019;86(6):417-425. 
  129. Kufel WD, et al. Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right? Hosp Pharm. 2017;52(3):214-220. 
  130. Smythe MA, et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. Thromb Thrombolysis. 2016;41(1):165-186. 
  131. Verhoeff K, et al. Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2022;93(2):61-70. 
  132. Witt DM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257-3291.
  133. Zuker-Herman R, et al. Comparison between two-point and three-point compression ultrasound for the diagnosis of deep vein thrombosis. Thromb Thrombolysis. 2018;45(1):99-105. 
  134. Needleman L, et al. Ultrasound for Lower Extremity Deep Venous Thrombosis: Multidisciplinary Recommendations From the Society of Radiologists in Ultrasound Consensus Conference. Circulation. 2018;137(14):1505-1515.
  135. Lim W, Le Gal G, Bates SM. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-3256.
  136. Maufus M, et al. Diagnosis of deep vein thrombosis recurrence: Ultrasound criteria. Thromb Res. 2018;161:78-83. 
  137. Goodacre S, et al. Systematic review and meta-analysis of the diagnostic accuracy of ultrasonography for deep vein thrombosis. BMC Med Imaging. 2005;5(1):6. 
  138. Righini M, et al. Clinical relevance of distal deep vein thrombosis. Review of literature data. Thromb Haemos. 2006;95(1):56-64. 
  139. Kraaijpoel N, et al. Diagnostic accuracy of three ultrasonography strategies for deep vein thrombosis of the lower extremity: A systematic review and meta-analysis. PLoS One. 2020;15(2):e0228788.
  140. Bernardi E, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA. 2008; 300(14):1653-1659.
  141. Gibson NS, et al. Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study. Thromb Thrombolysis. 2009;7(12):2035-2041.
  142. Hull RD, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation. 1983;67(4):901-906. 
  143. Tzoran I, et al. Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs. Thromb Haemost. 2012;10(4):564-571. 
  144. Stein PD, et al. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med. 2010;123(5):426-431. 
  145. Girard P, et al. Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med. 2001;164(6):1033-1037.
  146. García-Fuster MJ, et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord. 2014; 14(1):178. 
  147. Hughes MJ, Stein PD, Matta F. Silent pulmonary embolism in patients with distal deep venous thrombosis: systematic review. Thromb Res.2014; 134(6):1182-1185.
  148. Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor’s Choice ‒ efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg. 2014;48(5):565-575. 
  149. Barbar S, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. Thromb Haemost. 2010;8(11):2450-2457.
  150. Whitlock RP, Sun JC, Fremes SE. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):44-88. 
  151. Pandor A, et al. Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review. BMJ Open. 2021;11(7):e045672.
  152. Raskob GE, et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016;115(6):1240-1248.
  153. Gibson CM, et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. Thromb Haemost. 2017;1(1):56-65. 
  154. Spyropoulos AC, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706-714. 
  155. Pannucci CJ, et al. Individualized Venous Thromboembolism Risk Stratification Using the 2005 Caprini Score to Identify the Benefits and Harms of Chemoprophylaxis in Surgical Patients: A Meta-analysis. Ann Surg. 2017; 265(6):1094-1103.
  156. Hanh BM, et al. Determination of Risk Factors for Venous Thromboembolism by an Adapted Caprini Scoring System in Surgical Patients. J Pers Med. 2019;9(3):36. 
  157. Cramer JD, et al. Risk of Venous Thromboembolism Among Otolaryngology Patients vs General Surgery and Plastic Surgery Patients. JAMA Otolaryngol Neck Surg. 2017;144(1):9-17. 
  158. Grant PJ, et al. Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med. 2016; 129(5):528-535. 
  159. Lobastov KV, i dr. SHkala Caprini kak instrument dlya individual’noj stratifikacii riska razvitiya posleoperacionnyh venoznyh tromboembolij v gruppe vysokogo riska. Hirurgiya. Zhurnal im. N.I. Pirogova. 2014;114(12):16-23. (In Russ.).
  160. Pannucci CJ, et al. Postoperative enoxaparin prevents symptomatic venous thromboembolism in high-risk plastic surgery patients. Plast Reconstr Surg. 2011;128(5):1093-1103.
  161. Shuman AG, et al. Stratifying the risk of venous thromboembolism in otolaryngology. Otolaryngol Head Neck Surg. 2012;146(5):719-724. 
  162. Obi AT, Pannucci CJ, Nackashi A. Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients. JAMA Surg. 2015;150(10):941-948. 
  163. Yarlagadda BB, et al. Venous thromboembolism in otolaryngology surgical inpatients receiving chemoprophylaxis. Head Neck. 2014;36(8):1087-1093.
  164. Lobastov K, et al. Utilization of the Caprini score in conjunction with thrombodynamic testing reduces the number of unpredicted postoperative venous thromboembolism events in patients with colorectal cancer. J Vasc Surgery. 2020;8(1):31-41. 
  165. Lobastov K, et al. Validation of the Caprini risk assessment model for venous thromboembolism in high-risk surgical patients in the background of standard prophylaxis. J Vasc Surgery. 2016;4(2):153-160. 
  166. Paz Rios LH, et al. Validation of a Patient-Completed Caprini Risk Assessment Tool for Spanish, Arabic, and Polish Speakers. Clin Appl Thromb. 2018;24(3):502-512. 
  167. Fuentes HE, et al. Validation of a Patient-Completed Caprini Risk Score for Venous Thromboembolism Risk Assessment. Thromb Haemost. 2017; 1(2):106-112. 
  168. Chen X, et al. Clinical Validation of the Chinese Version of Patient Completed Caprini Risk Assessment Form. Clin Appl Thromb. 2020;(26): 107602962094503.
  169. Lobastov KV, Sautina EV. Konkurentnaya validaciya russkoyazychnoj versii pacient-orientirovannogo oprosnika na osnove shkaly Kaprini u hirurgicheskih pacientov. Flebologiya. 2022;1(16):6-15. (In Russ.).
  170. Khorana AA, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
  171. Verso M, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291-292. 
  172. Pelzer U, et al. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? DMW. 2013;138(41):2084-2088.
  173. van Es N, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. Ferrata Storti Foundation. 2017;102(9):1494-1501.
  174. van Es N, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. Thromb Haemost. 2020;18(8):1940-1951.
  175. Eichinger S, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636.
  176. Ensor J, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016;6(5):e011190.
  177. Tosetto A, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Thromb Haemost. 2012;10(6):1019-1025.
  178. van Hylckama Vlieg A., Baglin T.P. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study: reply. Thromb Haemost. 2015;13(12):2286-2287.
  179. Rodger MA, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417-426. 
  180. Rodger MA, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065.
  181. Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
  182. Brown JD, et al. Risk Stratification for Bleeding Complications in Patients With Venous Thromboembolism: Application of the HAS-BLED Bleeding Score During the First 6 Months of Anticoagulant Treatment. J Am Heart Assoc. 2018;7(6):e007901.
  183. Kooiman J, et al. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS One. 2015;10(4):e0122520.
  184. Zhu W, He W, Guo L. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. Clinical Cardiology. 2015;38(9):555-561. 
  185. Santise G, et al. The HAS-BLED Score is Associated With Major Bleeding in Patients After Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019;33(6):1601-1606.
  186. Castini D, et al. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome. Heart Vessels. 2019;34(10):1621-1630.
  187. Kresoja K-P, et al. Prediction and prognostic importance of in-hospital major bleeding in a real-world cohort of patients with pulmonary embolism. Int J Cardiol. 2019;290:144-149. 
  188. Klok FA, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir. 2016;48(5):1369-1376.
  189. Klok FA, et al. Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study. Br J Haematol. 2018;183(3):457-465. 
  190. Ruíz-Giménez N, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(1):26-31. 
  191. Palareti G, et al. The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism. Thromb Haemost. 2018;16(10):1994-2002.
  192. Klarin D, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019;51(11):1574-1579.
  193. Lindström S, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood. 2019; 134(19):1645-1657.
  194. Stevens S.M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. Thromb Thrombolysis. 2016;41(1):154-164. 
  195. Hirmerova J., Seidlerova J., Subrt I. The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox. QJM. 2014;107(9):715-720. 
  196. Poort SR, et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-3703.
  197. Emmerich J, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001; 86(3):809-816. 
  198. Wolberg A.S. Fibrinogen and factor XIII: Newly recognized roles in venous thrombus formation and composition. Current Opinion in Hematology. 2018;25(5):358-364. 
  199. Ahmad A, et al. Risk prediction of recurrent venous thromboembolism: a multiple genetic risk model. Thromb Thrombolysis. 2019;47(2):216-226. 
  200. Reshetnyak TM. Rekomendacii po lecheniyu antifosfolipidnogo sindroma. M. 2013. (In Russ.).
  201. Tektonidou MG, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304.
  202. Kulagin AD, Lisukov IA, Ptushkin VV, Shilova YR, et al. National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria. Oncohematology. 2014;9(2):20-28. (In Russ.).
  203. NICE. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. London: NICE; 2015.
  204. Baglin T, Luddington R, Brown K. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523-526. 
  205. Weingarz L, et al. Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. Br J Haematol. 2013;163(5):655-665. 
  206. Chechulova AV, et al. Genetic Markers of Hereditary Thrombophilia and the Clinical Course for Venous Thromboembolism in Young Patients from the North-West of Russian Federation. Flebologiia. 2020;14(1):6. 
  207. Coppens M, Reijnders JH, Middeldorp S. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. Thromb Haemost. 2008;6(9):1474-1477.
  208. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177-1187.
  209. Garcia-Horton A, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res. 2017;149:76-80. 
  210. Moll S. Thrombophilia: clinical-practical aspects. Thromb Thrombolysis. 2015;39(3):367-378. 
  211. Ortel TL, et al. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta‐analysis. Thromb Haemost. 2020;18(9):2274-2286.
  212. Somonova OV, Antuh EA, Elizarova AL. Prakticheskie rekomendacii po profilaktike i lecheniyu tromboembolicheskih oslozhnenij u onkologicheskih bol’nyh. Zlokachestvennye opuholi. 2017;7(3-S2):553-558. (In Russ.).
  213. Zhou M, et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis. Thromb Res. 2017;157:147-153. 
  214. Jara-Palomares L, et al. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest. 2017;151(3):564-571. 
  215. Lyman GH, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927-974. 
  216. Klein A, et al. Screening for occult cancer in idiopathic venous thromboembolism ‒ Systemic review and meta-analysis. Eur J Intern Med. 2017;42:74-80. 
  217. Kleinjan A, et al. Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med. 2012;70(7):311-317. 
  218. Robertson L, et al. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE. Cochrane Database Syst Rev. 2021;2021(10).
  219. Kalinin RE, Suchkov IA, Zemlyanukhin SP. Idiopathic Deep Vein Thrombosis: Choosing a Screening Strategy for Detecting Occult Cancer. Flebologiya. 2020;14(2):142-148. (In Russ.).
  220. Erlikh AD, et al. Pulmonary embolism in cancer patients. SIRENA register data. Flebologiya. 2021;15(3):179-186. (In Russ.).
  221. Ploton G, et al. A STROBE cohort study of 755 deep and superficial upper-extremity vein thrombosis. Medicine (Baltimore). 2020;99(6):e18996.
  222. Heil J, et al. Deep Vein Thrombosis of the Upper Extremity. Dtsch Arztebl Int. 2017;114(14):244-249. 
  223. Major KM, et al. Internal jugular, subclavian, and axillary deep venous thrombosis and the risk of pulmonary embolism. Vascular. 2008;16(2):73-79. 
  224. Mustafa S, et al. Upper extremity deep venous thrombosis. Chest. 2003; 123(6):1953-1956.
  225. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation. 2002;106(14):1874-1880.
  226. Sajid MS, et al. Upper limb deep vein thrombosis: a literature review to streamline the protocol for management. Acta Haematol. 2007;118(1):10-18. 
  227. Grant J.D, et al. Diagnosis and management of upper extremity deep-vein thrombosis in adults. Thromb Haemost. 2012;108(6):1097-1108.
  228. Flinterman L.E, et al. Current perspective of venous thrombosis in the upper extremity. Thromb Haemost. 2008;6(8):1262-1266.
  229. Martinelli I, et al. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation. 2004;110(5):566-570. 
  230. Hendler MF, et al. Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects. Am J Hematol. 2004;76(4):330-337. 
  231. Prandoni P, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med. 1997;157(1):57-62. 
  232. Di Nisio M, et al. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. Thromb Haemost. 2010;8(4):684-692. 
  233. Douma RA, et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med. 2011;154(11):709-718. 
  234. Wells PS, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2001;135(2):98-107. 
  235. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA. 1990;263(20):2753-2759.
  236. Lucassen W, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med. 2011;155(7):448-460. 
  237. van Belle A, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006;295(2):172-179. 
  238. Musset D, et al. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet. 2002; 360(9349):1914-1920.
  239. Perrier A, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet. 1999;353(9148):190-195. 
  240. Sostman HD, et al. Acute pulmonary embolism: sensitivity and specificity of ventilation-perfusion scintigraphy in PIOPED II study. Radiology. 2008;246(3):941-946. 
  241. Righini M, et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet. 2008;371(9621):1343-1352.
  242. Anderson DR, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007;298(23):2743-2753.
  243. Perrier A, et al. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med. 2004; 116(5):291-299. 
  244. Di Nisio M, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. Thromb Haemost. 2007;5(2):296-304. 
  245. Stein P.D, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med. 2004;140(8): 589-602. 
  246. Ceriani E, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. Thromb Haemost. 2010;8(5):957-970. 
  247. Patel S., Kazerooni E.A., Cascade P.N. Pulmonary embolism: optimization of small pulmonary artery visualization at multi-detector row CT. Radiology. 2003;227(2):455-460. 
  248. Ghaye B, et al. Peripheral pulmonary arteries: how far in the lung does multi-detector row spiral CT allow analysis? Radiology. 2001;219(3):629-636. 
  249. Carrier M, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. Thromb Haemost. 2010;8(8):1716-1722.
  250. Patel P, et al. Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism. Blood Adv. 2020;4(18):4296-4311.
  251. Qanadli SD, et al. Pulmonary embolism detection: prospective evaluation of dual-section helical CT versus selective pulmonary arteriography in 157 patients. Radiology. 2000;217(2):447-455. 
  252. Stein PD, et al. Complications and validity of pulmonary angiography in acute pulmonary embolism. Circulation. 1992;85(2):462-468. 
  253. Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. Circulation. 2011;124(19):2139-2144.
  254. Reid JH, et al. Is the lung scan alive and well? Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT. Eur J Nucl Med Mol Imaging. 2009;36(3):505-521. 
  255. Roy P-M, et al. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ. 2005;331(7511):259. 
  256. van Es J, et al. Accuracy of X-ray with perfusion scan in young patients with suspected pulmonary embolism. Thromb Res. 2015;136(2):221-224. 
  257. Kucher N, et al. Novel management strategy for patients with suspected pulmonary embolism. Eur Heart J. 2003;24(4):366-376. 
  258. Elliott CG, et al. Chest radiographs in acute pulmonary embolism. Results from the International Cooperative Pulmonary Embolism Registry. Chest. 2000;118(1):33-38. 
  259. Shopp JD, et al. Findings From 12-lead Electrocardiography That Predict Circulatory Shock From Pulmonary Embolism: Systematic Review and Meta-analysis. Acad Emerg Med. 2015;22(10):1127-1137.
  260. Revel MP, et al. Diagnostic accuracy of magnetic resonance imaging for an acute pulmonary embolism: results of the «IRM-EP» study. Thromb Haemost. 2012;10(5):743-750. 
  261. Stein PD, et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med. 2010;152(7):434-443. 
  262. Trujillo-Santos J, et al. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs. Am J Med. 2015; 128(1):90.e9-15. 
  263. Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2018;1(1):CD003076.
  264. Lozano F, et al. Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. J Vasc Surg. 2014;59(5):1362-7.e1. 
  265. Lobastov KV, Voroncova AV, Bargandzhiya AB. Ambulatornoe lechenie tromboza glubokih ven rivaroksabanom: opyt raboty v odnom centre. Flebologiya. 2020;14(2):99-106. (In Russ.).
  266. Barco S, et al. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J. 2020;41(4):509-518. 
  267. Broderick C, Watson L, Armon MP. Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database Syst Rev. 2021;1(1):CD002783.
  268. Lu Y, et al. Catheter-Directed Thrombolysis Versus Standard Anticoagulation for Acute Lower Extremity Deep Vein Thrombosis: A Meta-Analysis of Clinical Trials. Clin Appl Thromb Hemost. 2018;24(7):1134-1143.
  269. Foegh P, et al. Editor’s Choice ‒ Factors Associated with Long-Term Outcome in 191 Patients with Ilio-Femoral DVT Treated With Catheter-Directed Thrombolysis. Eur J Vasc Endovasc Surg. 2017;53(3):419-424. 
  270. Bezlepkin YuA, Son’kin IN, Gusinskiy AV, et al. Comparison of Long-Term Outcomes of Regional Catheter Thrombolysis and Standard Conservative Treatment for Proximal Deep Vein Thrombosis of Lower Extremities. Flebologiya. 2020;14(1):10-18. (In Russ.).
  271. Razavi MK, et al. Correlation between Post-Procedure Residual Thrombus and Clinical Outcome in Deep Vein Thrombosis Patients Receiving Pharmacomechanical Thrombolysis in a Multicenter Randomized Trial. J Vasc Interv Radiol. 2020;31(10):1517-1528.e2. 
  272. Huang C, Zhang W, Liang H. A retrospective comparison of thrombectomy followed by stenting and thrombectomy alone for the management of deep vein thrombosis with May-Thurner syndrome. J Vasc Surgery. 2021;9(3):635-642. 
  273. Lobastov KV, i dr. Diagnostika i lechenie hronicheskoj venoznoj obstrukcii: soglasovannoe mnenie rossijskih ekspertov (chast’ 2). Hirurg. 2020;7-8:22-55. (In Russ.).
  274. Comerota AJ, et al. Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. Circulation. 2019;139(9):1162-1173.
  275. Kearon C, et al. Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoral-Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. Thromb Haemost. 2019;119(04):633-644. 
  276. Notten P, Ten Cate H, Ten Cate-Hoek AJ. Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review. Thromb Haemost. 2021;19(3):753-796. 
  277. Sebastian T, et al. Cessation of anticoagulation therapy following endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. Vasa. 2019;48(4):331-339. 
  278. Limone BL, et al. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thromb Res. 2013;132(4):420-426. 
  279. Kearon C, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. 
  280. Kearon C, Kahn SR. Long-term treatment of venous thromboembolism. Blood. 2020;135(5):317-325. 
  281. Heit JA, et al. Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. Thromb Res. 2015;136(2):298-307. 
  282. Douketis J, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153(8):523-531. 
  283. Kearon C, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015;162(1):27-34. 
  284. Donadini MP, et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb. 2014;111(1):172-179. 
  285. Prandoni P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12):955-960. 
  286. Prandoni P, et al. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res. 2017;153:97-100. 
  287. Siragusa S, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112(3):511-515. 
  288. Lobastov K, et al. Electrical calf muscle stimulation in patients with post-thrombotic syndrome and residual venous obstruction after anticoagulation therapy. Int Angiol. 2018;37(5):400-410. 
  289. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: Risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29(3):298-310. 
  290. Palareti G. Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo). 2012;2012:391734.
  291. Ho WK, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006; 166(7):729-736. 
  292. Áinle FN, Kevane B. Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)? Blood Adv. 2020;4(21):5595-5606.
  293. Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114(5):885-889. 
  294. Croles FN, et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017; 359:j4452.
  295. van Vlijmen EFW, et al. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. Thromb Haemost. 2016;14(7):1393-1403.
  296. Campello E, et al. Thrombophilia, risk factors and prevention. Expert Rev. Hematol. 2019;12(3):147-158. 
  297. Marcucci M, et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Thromb Haemost. 2015;13(5):775-781. 
  298. Klok FA, Huisman MV. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. Blood. 2020;135(10):724-734. 
  299. Marques Antunes M, et al. The high-risk bleeding category of different scores in patients with venous thromboembolism: Systematic review and meta-analysis. Eur J Intern Med. 2021;94:45-55. 
  300. Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europea. Eur Heart J. 2021;42(5):373-498. 
  301. Steffel J, Heidbüchel H. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment — Authors’ reply. EP Eur. 2021;23(10): 1685-1686.
  302. Schulman S, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Thromb Haemost. 2010;8(1):202-204. 
  303. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Thromb Haemost. 2005;3(4):692-694. 
  304. Kaatz S, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. Thromb Haemost. 2015;13(11):2119-2126.
  305. Boutitie F, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342(may24 2):d3036.
  306. Nieto JA, et al. Thirty-day outcomes in patients with proximal deep vein thrombosis who discontinued anticoagulant therapy prematurely. Thromb Res. 2020;189:61-68. 
  307. Middeldorp S, Prins MH, Hutten BA. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2014;2014(8):CD001367.
  308. Punthakee X, Doobay J, Anand SS. Oral-anticoagulant-related intracerebral hemorrhage. Thromb Res. 2002;108(1):31-36. 
  309. Linkins L-A, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139(11):893-900. 
  310. Carrier M, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152(9):578-589. 
  311. Ebraheem M, et al. Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta-analysis. Thromb Haemost. 2020;18(9):2308-2317.
  312. Petrikov AS, Dudin DV, Dronov SV, Eyrikh VR, Shoykhet YaN. Lower Extremity Deep Vein Recanalization Following Prolonged Antithrombotic Therapy and D-dimer, C-reactive Protein and Homocysteine Levels. Flebologiya. 2020;14(3):196-204. (In Russ.).
  313. Agnelli G, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. 
  314. Weitz JI, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;376(13):1211-1222.
  315. Brighton TA, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979-1987.
  316. Becattini C, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959-1967.
  317. Simes J, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062-1071.
  318. Koroleva LYu, Nosov VP, Zlobina DS, Sadyrin RV. Rivaroxaban in the Treatment and Long-Term Prevention of Recurrent VTEC in Patients with Pulmonary Embolism. Flebologiya. 2021;15(3):199-204. (In Russ.).
  319. Mai V, et al. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLoS One. 2019;14(4):e0214134.
  320. Jiang Q-J, et al. Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Front. 2018;9:876. 
  321. Franco L, et al. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. Thromb Haemost. 2017;15(6):1142-1154.
  322. Bradbury C, et al. A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE the Ex. Br J Haematol. 2020;188(6):962-975. 
  323. Aziz D, et al. Long‐term risk of recurrent venous thromboembolism after a first contraceptive‐related event: Data from REVERSE cohort study. Thromb Haemost. 2021;19(6):1526-1532.
  324. White RH, Murin S, Wun T. Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. Thromb Haemost. 2010;8(5):987-997. 
  325. Le Gal G, et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost. 2010;104(3):498-503. 
  326. Vaillant-Roussel H, et al. Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives. Contraception. 2011; 84(5):23-30. 
  327. Martinelli I, Lensing AWA, Middeldorp S. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127(11):1417-1425.
  328. Ageno W, et al. Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. Res Pract Thromb Haemost. 2021;5(2): 326-341. 
  329. Djulbegovic M, Lee AI, Chen K. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta‐analysis, and decision analysis. J Eval Clin Pract. 2020;26(1):7-17. 
  330. Kahn SRS, Julian JJA, Kearon C. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg. 2020;8(1):8-23. 
  331. Robertson L, Yeoh SE, Ramli A. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Cochrane Database Syst Rev. 2017;12(12):CD011088.
  332. Schulman S, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336(6):393-398. 
  333. Kahale LA, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018; 6(6):CD006650.
  334. Marshall A, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). Thromb Haemost. 2020;18(4):905-915. 
  335. Dufrost V, Wahl D, Zuily S. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials. Autoimmun Rev. 2021;20(1):102711.
  336. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998;104(4):332-338. 
  337. Kirkilesis G, et al. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev. 2020;4(4):CD013422.
  338. Hokusai-VTE Investigators; Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.
  339. Pesavento R, et al. Fondaparinux in the initial and long-term treatment of venous thromboembolism. Thromb Res. 2015;135(2):311-317. 
  340. Cohen AT, et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS One. 2015;10(12):e0144856.
  341. Agnelli G, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. 
  342. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
  343. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297.
  344. Schulman S, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-772. 
  345. Amin A, et al. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. J Med Econ. 2014;17(11):763-770. 
  346. Law S, et al. A pharmacoeconomic study of traditional anticoagulation versus direct oral anticoagulation for the treatment of venous thromboembolism in the emergency department. CJEM. 2016;18(5):340-348. 
  347. Amin A, et al. Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States. Clin Appl Thromb. 2016;22(1):5-11. 
  348. Millar CM, Laffan MA. Drug therapy in anticoagulation: which drug for which patient? Clin Med. 2017;17(3):233-244. 
  349. Smith SB, et al. Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest. 2010;137(6):1382-1390.
  350. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140(3):175-183. 
  351. Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017;2(2):CD001100.
  352. Robertson L, Strachan J. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017;2(2):CD006771.
  353. Cossette B, Pelletier M-È, Carrier N. Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother. 2010;44(6):994-1002.
  354. Prandoni P, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049-3054.
  355. Meyer G, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-1411.
  356. Vedantham S, et al. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2014;25(9):1317-1325.
  357. Graif A, et al. Safety of Therapeutic Anticoagulation with Low-Molecular-Weight Heparin or Unfractionated Heparin Infusion during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism. J Vasc Interv Radiol. 2020;31(4):537-543. 
  358. Li Y, Wang J, He R. Feasibility of anticoagulation using low molecular-weight heparin during catheter-directed thrombolysis for lower extremity deep venous thrombosis Thromb. 2021;19(1):1-7. 
  359. Hull RD, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med. 1997;157(22): 2562-2568.
  360. Büller HR, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867-873. 
  361. Warkentin TE, Maurer BT, Aster RH. Heparin-Induced Thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356(25):2653-2655.
  362. Konstantinides SV, et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(43):3033-3080.
  363. Barginear MF, et al. Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. Support. Care Cancer. 2012;20(11):2865-2872.
  364. Bhatt VR, et al. Fondaparinux-associated heparin-induced thrombocytopenia. Eur J Haematol. 2013;91(5):437-441. 
  365. Savi P, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood. 2005;105(1):139-144. 
  366. Warkentin TE, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. Thromb Haemost. 2011;9(12):2389-2396.
  367. Schindewolf M, et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study. Thromb Res. 2014;134(1):29-35. 
  368. Kang M, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125(6): 924-929. 
  369. Lobo B, et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008;99(1):208-214. 
  370. Benken ST, et al. A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients. J Cardiothorac Surg. 2014;9(1):55. 
  371. Cegarra-Sanmartín V, et al. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. J Cardiothorac Vasc Anesth. 2014;28(4):1008-1012.
  372. Research and Practice in Thrombosis and Haemostasis. Res Pract Thromb Haemost. 2020;4(S1):1-1311.
  373. Vorob’eva NA, Vorob’eva AI, Shemyakina NYa. Pacient-orientirovannyj podhod kak osnova povysheniya effektivnosti i bezopasnosti antitromboticheskoj terapii u komorbidnyh pacientov. Rol’ antikoagulyantnyh kabinetov. Klinicheskaya gerontologiya. 2019;25(11-12):19-24. (In Russ.).
  374. Liu M, Zhang F. Administration routes affect thrombolytic effect of catheter-directed thrombolysis with pro-urokinase in treating deep vein thrombosis. Ann Transl Med. 2018;6(16):322. 
  375. Kearon C, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12):901-907. 
  376. Ridker PM, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15): 1425-1434.
  377. Raskob G, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet. Haematol. 2016;3(5):e228-36. 
  378. Schulman S, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718. 
  379. Andreozzi GM, et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism. Circulation. 2015;132(20):1891-1897.
  380. Andras A, Sala Tenna A, Stewart M. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2017;2017(7):CD002001.
  381. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. Thromb Haemost. 2003;1(9):1906-1913.
  382. Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med. 2011;124(8):756-765. 
  383. Wawrzyńska L, et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb. 2003;33(2):64-67. 
  384. Linkins L-A, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):495-530. 
  385. Pompilio G, et al. Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis. TH Open. 2020;04(02):80-93. 
  386. Savel’ev VS, Gologorskij VA, Kirienko AI. Flebologiya. M.: Medicina; 2001.
  387. Gloviczki P. Handbook of venous and lymphatic disorders: guidelines of the American Venous Forum. CRC Press. 2017.
  388. Kearon C, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med. 1998;128(8):663-677. 
  389. Messina LM, et al. Clinical significance of routine imaging of iliac and calf veins by color flow duplex scanning in patients suspected of having acute lower extremity deep venous thrombosis. Surgery. 1993;114(5):921-927. 
  390. Sampson F, Goodacre S, Thomas S. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol. 2007;17(1):175-181. 
  391. Thomas S, Goodacre S, Sampson F. Diagnostic value of CT for deep vein thrombosis: results of a systematic review and meta-analysis. Clin Radiol. 2008;63(3):299-304. 
  392. AbuRahma AFA, et al. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg. 2001;233(6):752. 
  393. Baekgaard N, et al. Long-term results using catheter-directed thrombolysis in 103 lower limbs with acute iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg. 2010;39(1):112-117. 
  394. Notten P, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol. 2020; 7(1):40-49. 
  395. Enden T, Haig Y, Kløw NN-E. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379(9810):31-38. 
  396. Sharifi M, Bay C, Mehdipour M. Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results. J Endovasc Ther. 2012;19(2):273-280. 
  397. Vedantham S, Goldhaber SSZ, Julian JJA. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017; 377(23):2240-2252.
  398. Sharifi M, Mehdipour M, Bay, Csmith G. Endovenous therapy for deep venous thrombosis: the TORPEDO trial. Catheter Cardiovasc Interv. 2010; 76(3):316-325. 
  399. Protack CD, et al. Long-term outcomes of catheter directed thrombolysis for lower extremity deep venous thrombosis without prophylactic inferior vena cava filter placement. J Vasc Surg. 2007;45(5):992-997; discussion 997. 
  400. Mewissen MW, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 1999;211(1):39-49. 
  401. Lin PPH, Zhou W, Dardik A. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. Am J Surg. 2006;192(6):782-788. 
  402. Arko FR, Davis CCM, Murphy EEH. Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results. Arch Surg. 2007;142(6):513-518. 
  403. Martinez Trabal J, Comerota AA, LaPorte FFBF. The quantitative benefit of isolated, segmental, pharmacomechanical thrombolysis (ISPMT) for iliofemoral venous thrombosis. J Vasc Surg. 2008;48(6):1532-1537.
  404. Tsai J, Georgiades CCS, Hong K. Presumed pulmonary embolism following power-pulse spray thrombectomy of upper extremity venous thrombosis. Cardiovasc Intervent. Radiol. 2006;29(4):678-680. 
  405. Eklof B, Mclafferty RB. Surgical thrombectomy and percutaneous mechanical thrombectomy for treatment of acute iliofemoral venous thrombosis. Handbook of Venous Disorders: Guidelines of the American Venous Forum Third Edition. CRC Press; 2008;255. 
  406. Vedantham S, et al. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2014;25(9):1317-1325.
  407. Ashrafi M, et al. Treatment Strategies for Proximal Deep Vein Thrombosis: A Network Meta-analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2022;63(2):323-334. 
  408. Casey ET, et al. Treatment of acute iliofemoral deep vein thrombosis. J Vasc Surg. 2012;55(5):1463-1473.
  409. Lebedev IS, Maslennikov MA, Leont’ev SG, Kim TG, Kirienko AI. Pharmacomechanical Recanalization of the Major Veins in Phlegmasia Cerulea Dolens Caused by Embolic Occlusion of Cava Filter. Flebologiya. 2020;14(1):40-45. (In Russ.).
  410. Plate G, Eklöf B, Norgren L. Venous thrombectomy for iliofemoral vein thrombosis: 10-year results of a prospective randomised study. Eur J Vasc Endovasc. 1997;14(5):367-374. 
  411. Rodríguez L, Aboukheir-Aboukheir A, Figueroa-Vicente R. Hybrid operative thrombectomy is noninferior to percutaneous techniques for the treatment of acute iliofemoral deep venous thrombosis. J Vasc Surgery Venous Lymphat Disord. 2017;5(2):177-184. 
  412. Karthikesalingam A, et al. A systematic review of percutaneous mechanical thrombectomy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2011;41(4):554-565. 
  413. Blättler W, Heller G, Largiadèr J. Combined regional thrombolysis and surgical thrombectomy for treatment of iliofemoral vein thrombosis. J Vasc Surg. 2004;40(4):620-625. 
  414. Comerota AAJ, Gale SS. Technique of contemporary iliofemoral and infrainguinal venous thrombectomy. J Vasc Surg. 2006;43(1):185-191. 
  415. Hölper P, et al. Longterm results after surgical thrombectomy and simultaneous stenting for symptomatic iliofemoral venous thrombosis. Eur J Vasc Endovasc Surg. 2010;39(3):349-355. 
  416. Husmann MJ, et al. Stenting of common iliac vein obstructions combined with regional thrombolysis and thrombectomy in acute deep vein thrombosis. Eur J Vasc Endovasc Surg. 2007;34(1):87-91. 
  417. Lindow C, et al. Long-term results after transfemoral venous thrombectomy for iliofemoral deep venous thrombosis. Eur J Vasc Endovasc Surg. 2010;40(1):134-138. 
  418. Schwarzbach MHM, et al. Surgical Thrombectomy Followed by Intraoperative Endovascular Reconstruction for Symptomatic Ilio-femoral Venous Thrombosis. Eur J Vasc Endovasc Surg. 2005;29(1):58-66. 
  419. Lichtenberg MKW, et al. Endovascular mechanical thrombectomy versus thrombolysis in patients with iliofemoral deep vein thrombosis ‒ a systematic review and meta-analysis. Vasa. 2021;50(1):59-67. 
  420. Hull R.D, et al. Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. Am J Med. 2005;118(5):456-464. 
  421. Haig Y, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016;3(2):64-71. 
  422. Engelberger RP, et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: 1-year follow-up data of a randomized-controlled trial. Thromb Haemost. 2017;15(7): 1351-1360.
  423. Garcia M, Lookstein R, Malhotra R. Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry. J Vasc Interv Radiol. 2015;26(6):777-785. 
  424. Goldhaber SZ, et al. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med. 1984;76(3):393-397. 
  425. Schwieder G, et al. Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT): a German multicenter trial. Thromb Haemost. 1995;74(5):1240-1243.
  426. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2016;11(11):CD002783.
  427. Vedantham S, Thorpe PPE, Cardella JJF. Quality improvement guidelines for the treatment of lower extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2009;20(7 suppl):227-239. 
  428. Bækgaard N, Klitfod L, Broholm R. Safety and efficacy of catheter-directed thrombolysis. Phlebology. 2012;27(1 suppl):149-154. 
  429. Bækgaard N, Klitfod L, Jørgensen M. Should catheter-directed thrombolysis be monitored? Phlebology. 2016;31(1 suppl):5-10. 
  430. Chaar CIO. Current Management of Venous Diseases. Ed. Chaar C.I.O. Cham: Springer International Publishing; 2018.
  431. Kohi MM, Kohlbrenner R, Kolli KKP. Catheter directed interventions for acute deep vein thrombosis. Cardiovasc Diagn Ther. 2016;6(6):599. 
  432. Watson L, Armon M. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2014;(1):CD002783.
  433. Jeyabalan G, et al. Inflow thrombosis does not adversely affect thrombolysis outcomes of symptomatic iliofemoral deep vein thrombosis. J Vasc Surg. 2011;54(2):448-453. 
  434. Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol. 2004;15(4):347-352. 
  435. Sugimoto K, Hofmann LVL. Razavi MMK. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg. 2003;37(3):512-517. 
  436. Sillesen H, et al. Catheter directed thrombolysis for treatment of ilio-femoral deep venous thrombosis is durable, preserves venous valve function and may prevent chronic venous insufficiency. Eur J Vasc Endovasc Surg. 2005;30(5):556-562. 
  437. Verhaeghe R, et al. Catheter-directed lysis of iliofemoral vein thrombosis with use of rt-PA. Eur Radiol. 1997;7(7):996-1001.
  438. Engelberger RP, et al. Fixed low-dose ultrasound-assisted catheter-directed thrombolysis followed by routine stenting of residual stenosis for acute ilio-femoral deep-vein thrombosis. Thromb Haemost. 2014;111(6):1153-1160.
  439. Comerota AJ. The ATTRACT Trial: Rationale for Early Intervention for Iliofemoral DVT. Perspect Vasc Surg Endovasc Ther. 2009;21(4):221-225. 
  440. Semba CP, et al. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol. 2000; 11(3):279-287. 
  441. Ogawa T, Hoshino S, Midorikawa H. Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg. J Vasc Surg. 2005;42(5):940-944. 
  442. Vedantham S, et al. Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis. J Vasc Interv Radiol. 2004;15(6): 565-574. 
  443. Bush RL, et al. Pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis: safety and feasibility study. J Vasc Surg. 2004;40(5):965-970. 
  444. Kim HS, et al. Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes. J Vasc Interv Radiol. 2006;17(7):1099-1104.
  445. Diniz J, Coelho A, Mansilha A. Endovascular treatment of iliofemoral deep venous thrombosis: is there enough evidence to support it? A systematic review with meta-analysis. Int Angiol. 2020;39(2).
  446. Escobar GAG, Burks D, Abate MMRM. Risk of acute kidney injury after percutaneous pharmacomechanical thrombectomy using AngioJet in venous and arterial thrombosis. Ann Vasc Surg. 2017;(42):238-245. 
  447. Shen Y, Wang X, Jin SS. Increased risk of acute kidney injury with percutaneous mechanical thrombectomy using AngioJet compared with catheter-directed thrombolysis. J Vasc Surg Venous Lymphat Disord. 2019;7(1):29-37. 
  448. Morrow KKL, Kim AAH, Plato S. Increased risk of renal dysfunction with percutaneous mechanical thrombectomy compared with catheter-directed thrombolysis. J Vasc Surg. 2017;65(5):1460-1466.
  449. Minko P, et al. Mechanical thrombectomy of iliac vein thrombosis in a pig model using the Rotarex and Aspirex catheters. Cardiovasc Intervent Radiol. 2014;37(1):211-217. 
  450. Lichtenberg M, Stahlhoff W, Özkapi A. Safety, procedural success and outcome of the Aspirex S endovascular thrombectomy system in the treatment of iliofemoral deep vein thrombosis — data from the Arnsberg Aspirex registry. Vasa. 2019;48(4):341-346. 
  451. Loffroy R, Falvo N, Guillen K. Single-Session Percutaneous Mechanical Thrombectomy Using the Aspirex S Device Plus Stenting for Acute Iliofemoral Deep Vein Thrombosis: Safety, Efficacy, and Mid-Term Outcomes. Diagnostics. 2020;10(8):544. 
  452. Deák Z, Strube H, Sadeghi-Azandaryani M. Rotational thrombectomy of acute peripheral vascular occlusions using the ThromCat XT device: techniques, indications and initial results. Diagnostic Interv Radiol. 2011; 17(3):283. 
  453. Delomez M, et al. Mechanical thrombectomy in patients with deep venous thrombosis. Cardiovasc Intervent Radiol. 2001;24(1):42-48. 
  454. Gandini R, et al. Percutaneous ilio-caval thrombectomy with the Amplatz device: preliminary results. Eur Radiol. 1999;9(5):951-958. 
  455. Lee K-H, et al. Mechanical thrombectomy of acute iliofemoral deep vein thrombosis with use of an Arrow-Trerotola percutaneous thrombectomy device. J Vasc Interv Radiol. 2006;17(3):487-495. 
  456. Prozorov SA, i dr. Udalenie flotiruyushchih trombov iz nizhnej poloj veny. Endovaskulyarnaya hirurgiya. 2017;4(1):39-44. (In Russ.).
  457. Kapranov SA. Endovaskulyarnaya hirurgiya pri zabolevaniyah venoznoj sistemy: vozmozhnosti i perspektivy. Flebologiya. 2007;1(1):29. (In Russ.).
  458. Rajput F, Du L, Woods M. Percutaneous vacuum-assisted thrombectomy using angioVac aspiration system. Cardiovasc Revascularization Med. 2020;21(4):489-493. 
  459. Lopez R, DeMartino R, Fleming M. Aspiration thrombectomy for acute iliofemoral or central deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2019;7(2):162-168. 
  460. Hariri A, et al. Use of a novel mechanical rinsing and aspiration thrombectomy device for treatment of deep venous and arteriovenous graft thrombosis. J Vasc Interv Radiol. 2007;18(2):313-316. 
  461. Heberlein WE, et al. New generation aspiration catheter: Feasibility in the treatment of pulmonary embolism. World J Radiol. 2013;5(11):430-435. 
  462. Wang W, Sun R, Chen Y. Meta-analysis and systematic review of percutaneous mechanical thrombectomy for lower extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2018;6(6):788-800. 
  463. Alkhouli M, et al. Inferior Vena Cava Thrombosis. JACC Cardiovasc. 2016; 9(7):629-643. 
  464. McAree BJ, et al. Inferior vena cava thrombosis: a review of current practice. Vasc Med. 2013;18(1):32-43. 
  465. Kaufman JA, et al. Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease: Developed in collaboration with the American College of Cardiology, American College of Chest P. J Vasc Interv Radiol. 2020;31(10):1529-1544.
  466. Stein PD, Matta F, Yaekoub AY. Incidence of vena cava thrombosis in the United States. Am J Cardiol. 2008;102(7):927-929. 
  467. Sharifi M, et al. Role of IVC filters in endovenous therapy for deep venous thrombosis: the FILTER-PEVI (filter implantation to lower thromboembolic risk in percutaneous endovenous intervention) trial. Cardiovasc Intervent Radiol. 2012;35(6):1408-1413.
  468. Avgerinos ED, et al. Inferior vena cava filter placement during thrombolysis for acute iliofemoral deep venous thrombosis. J Vasc Surgery Venous Lymphat Disord. 2014;2(3):274-281. 
  469. Black SA, et al. Management of acute and chronic iliofemoral venous outflow obstruction: a multidisciplinary team consensus. Int Angiol. 2020;39(1):3-16. 
  470. Chick JB, et al. Endovascular Iliocaval Stent Reconstruction for Inferior Vena Cava Filter-Associated Iliocaval Thrombosis: Approach, Technical Success, Safety, and Two-Year Outcomes in 120 Patients. J Vasc Interv Radiol. 2017;28(7):933-939. 
  471. Group PS. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112(3):416-422. 
  472. Kölbel T, et al. Thrombus embolization into IVC filters during catheter-directed thrombolysis for proximal deep venous thrombosis. J Endovasc Ther. 2008;15(5):605-613. 
  473. Lebedev IS, et al. Ovarian Vein Thrombosis Extending to Inferior Vena Cava in Postpartum Period: Case Reports and Literature Review. Flebologiya. 2020;14(3):244-252. (In Russ.).
  474. Meissner MH, et al. Early thrombus removal strategies for acute deep venous thrombosis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2012;55(5):1449-1462.
  475. Weaver FA, et al. Phlegmasia cerulea dolens: therapeutic considerations. South Med J. 1988;81(3):306-312. 
  476. Fasolini FG, Streuli HK. Thrombectomy versus conservative therapy of thrombosis of the deep veins of the pelvis and legs. Late results 10 years later. Helv Chir Acta. 1985;52(5):735-738. 
  477. Gänger KH, et al. Surgical thrombectomy versus conservative treatment for deep venous thrombosis; functional comparison of long-term results. Eur J Vasc Surg. 1989;3(6):529-538. 
  478. Hamilton H, et al. Venous thrombectomy in patients presenting with iliofemoral vein thrombosis after renal transplantation. Transpl Int. 1996;9(5): 513-516. 
  479. Hold M, et al. Deep venous thrombosis: results of thrombectomy versus medical therapy. Presented at the 5th European-American Symposium on Venous Diseases, Vienna, Austria, Nov. 7—11, 1990. Vasa. 1992;21(2):181-187. 
  480. Matsubara J, et al. Long-term follow-up results of the iliofemoral venous thrombosis. J Cardiovasc Surg (Torino). 1976;17(3):234-239. 
  481. Plate G, Einarsson E, Ohlin P. Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis. J Vasc Surg.1984;1(6):867-876. 
  482. Sato S, et al. Conservative treatment of acute deep vein thrombosis of lower extremities. Nihon Geka Gakkai Zasshi. 1992;93(9):1052-1054.
  483. Stiegler H, et al. Operation, lysis, heparin therapy: 3 equally valid forms of therapy in acute leg-pelvic venous thrombosis. Vasa. Suppl. 1987;20:153-156. 
  484. Törngren S, et al. The long-term outcome of proximal vein thrombosis during pregnancy is not improved by the addition of surgical thrombectomy to anticoagulant treatment. Eur J Vasc Endovasc Surg. 1996;12(1):31-36. 
  485. Seager MJ, et al. Editor’s Choice: A Systematic Review of Endovenous Stenting in Chronic Venous Disease Secondary to Iliac Vein Obstruction. Eur J Vasc Endovasc Surg. 2016;51(1):100-120. 
  486. Eijgenraam P, ten Cate H, ten Cate-Hoek AJ. Venous stenting after deep venous thrombosis and antithrombotic therapy: A systematic review. Rev Vasc Med. 2014;2(3):88-97. 
  487. Breen K, Breen K. Role of venous stenting for venous thromboembolism. Hematol Am Soc Hematol. 2020;2020(1):606-611. 
  488. Hage A, Srinivasa R, Abramowitz S. Endovascular Iliocaval Stent Reconstruction for Iliocaval Thrombosis: A Multi-Institutional International Practice Pattern Survey. Ann Vasc Surg. 2018;(49):64-74. 
  489. Milinis K, et al. Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus. Eur J Vasc Endovasc Surg. 2018;55(4):537-544. 
  490. Taha MMAH, Busuttil A, Bootun R. A systematic review on the use of deep venous stenting for acute venous thrombosis of the lower limb. Phlebology. 2019;34(2):115-127. 
  491. Bækgaard N, Broholm R, Just S. Indications for stenting during thrombolysis. Phlebology. 2013;28(1 suppl):112-116. 
  492. Meng Q-Y, et al. Stenting of iliac vein obstruction following catheter-directed thrombolysis in lower extremity deep vein thrombosis. Chin Med J (Engl). 2013;126(18):3519-3522.
  493. Raju S. Treatment of iliac-caval outflow obstruction. Semin Vasc Surg. 2015; 28(1):47-53. 
  494. Razavi M, Jaff M, Miller L. Safety and Effectiveness of Stent Placement for Iliofemoral Venous Outflow Obstruction: Systematic Review and Meta-Analysis. Circ Cardiovasc Interv. 2015;8:10. 
  495. Rodrigues L, Bertanha M, El Dib R. Association between deep vein thrombosis and stent patency in symptomatic iliac vein compression syndrome: Systematic review and meta-analysis. J Vasc Surgery Venous Lymphat Disord. 2021;9(1):275-284. 
  496. Raju S, Owen S, Neglen P. The clinical impact of iliac venous stents in the management of chronic venous insufficiency. J Vasc Surg. 2002;35(1):8-15. 
  497. May R, Thurner J. The cause of the predominantly sinistral occurrence of thrombosis of the pelvic veins. Angiology. 1957;8(5):419-427. 
  498. Cockett FB, Thomas ML. The iliac compression syndrome. Br J Surg. 1965; 52(10):816-821. 
  499. Ochoa Chaar C, Aurshina A. Endovascular and Open Surgery for Deep Vein Thrombosis. Clin Chest Med. 2018;39(3):631-644. 
  500. Majeed GM, et al. A Systematic Review and Meta-Analysis of 12-Month Patency After Intervention for Iliofemoral Obstruction Using Dedicated or Non-Dedicated Venous Stents. J Endovasc Ther. 2022;29(3):478-492. 
  501. Garcia R, et al. Present and future options for treatment of infrainguinal deep vein disease. J Vasc Surgery Venous Lymphat Disord. 2018;6(5):664-671. 
  502. DeYoung E, Minocha J. Inferior Vena Cava Filters: Guidelines, Best Practice, and Expanding Indications. Semin Intervent Radiol. 2016;33(2):65-70. 
  503. Arslanbekov MM, Efremova OI, Zolotuhin IA. Emboliya v kava-fil’tr: kriterii, razrabotannye s ispol’zovaniem modificirovannogo metoda Delphi. Flebologiya. 2020;14(3):184-188. (In Russ.).
  504. Liu Y, et al. Effect of inferior vena cava filters on pulmonary embolism-related mortality and major complications: a systematic review and meta-analysis of randomized controlled trials. J Vasc Surgery Venous Lymphat Disord. 2021;9(3):792-800.e2. 
  505. Ahmed O, et al. Inferior Vena Cava Filter Evaluation and Management for the Diagnostic Radiologist: A Comprehensive Review Including Inferior Vena Cava Filter-Related Complications and PRESERVE Trial Filters. Can Assoc Radiol J. 2019;70(4):367-382. 
  506. Gillespie DL, et al. Predicting the Safety and Effectiveness of Inferior Vena Cava Filters Study: Design of a unique safety and effectiveness study of inferior vena cava filters in clinical practice. J Vasc Surgery Venous Lymphat Disord. 2020;8(2):187-194.e1. 
  507. Kaufman JA, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. Surg Obes Relat Dis. 2006;2(2):200-212. 
  508. Mismetti P, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA. 2015;313(16):1627-1635.
  509. Decousus H, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409-415. 
  510. White RH, et al. Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism. Circulation. 2016;133(21):2018-2029.
  511. Jaff MR, et al. Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2011;123(16):1788-1830.
  512. Zolotukhin IA, Arslanbekov MM, Efremova OI, Lebedev IS, Leontiev SG, Kirienko AI. Validity of Indications for Inferior Vena Cava Filter Placement in Patients with Venous Thromboembolism. Flebologiya. 2021;15(2): 80-86. (In Russ.).
  513. Norris CS, Greenfield LJ, Herrmann JB. Free-floating iliofemoral thrombus. A risk of pulmonary embolism. Arch Surg. 1985;120(7):806-808. 
  514. Streiff MB. Vena caval filters: a comprehensive review. Blood. 2000;95(12): 3669-3677.
  515. Zhao H, et al. Comparison of the in vitro clot-capturing efficiencies of commercially available retrievable inferior vena cava filters. J Vasc Surgery Venous Lymphat Disord. 2022;10(2):463-468.e2. 
  516. Porembskaya O.Ya, i dr. Legochnaya emboliya ‒ razroznennye chasti nesobrannoj mozaiki. Flebologiya. 2021;15(3):188. (In Russ.).
  517. Caplin DM, et al. Quality improvement guidelines for the performance of inferior vena cava filter placement for the prevention of pulmonary embolism. J Vasc Interv Radiol. 2011;22(11):1499-1506.
  518. ACR-SIR-SPR practice parameter for the performance of inferior vena cava filter placement for the Prevention of Pulmonary Embolism. Fairfax, VA: American College of Radiology/Society of Interventional Radiology; 2016.
  519. Ni H, Win LLL. Retrievable inferior vena cava filters for venous thromboembolism. Int Sch Res Not. 2013;2013:1-8. 
  520. Imberti D, et al. Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. Thromb Haemost. 2005;3(7):1370-1375.
  521. Dake MMD, Murphy TTPT, Krämer AAH. One-year analysis of the prospective multicenter SENTRY clinical trial: safety and effectiveness of the Novate Sentry Bioconvertible Inferior Vena Cava Filter. J Vasc Interv Radiol. 2018;29(10):1350-1361.
  522. Le Blanche AF, et al. The optional VenaTech Convertible (TM) vena cava filter: experimental study in sheep. Cardiovasc Intervent Radiol. 2012;35(5): 1181-1187.
  523. Kusuyama T, et al. Patient with a massive idiopathic thrombosis in the inferior vena cava. Ann Vasc Dis. 2012;5(1):89-91. 
  524. Smith SJ, et al. Vacuum-assisted thrombectomy device (AngioVac) in the management of symptomatic iliocaval thrombosis. J Vasc Interv Radiol. 2014;25(3):425-430. 
  525. Gavrilov EK, Tarasov VA, Khubulava GG. Experience in Diagnostics, Tactics, and Surgical Interventions in Patients with Inferior Vena Cava Obstruction of Different Origins. Flebologiya. 2020;14(4):346-355. (In Russ.).
  526. Ignat’ev IM, Akchurin FR, Zanochkin AV, Volodiukhin MIu, Bredikhin RA. The experience with the treatment of floating thrombi in the inferior vena cava system. Flebologiya. 2011;5(4):44-51. (In Russ.).
  527. Kirienko AI, Andriyashkin VV, Ivanov VV. Otkrytye operativnye vmeshatel’stva v lechenii bol’nyh s pozdnimi oslozhneniyami implantacii kava-fil’trov. Flebologiya. 2018;12(1):4-11. (In Russ.).
  528. Kirienko AI, Andriyashkin VV, Lebedev IS. Tromboz suprarenal’nogo otdela nizhnej poloj veny i pravogo predserdiya pri rake zheludka. Hirurgiya. Zhurnal im. N.I. Pirogova. 2014;8:81-82. (In Russ.).
  529. D’Ayala M, et al. Factors Associated with Successful Thrombus Extraction with the AngioVac Device: An Institutional Experience. Ann Vasc Surg. 2017;38:242-247. 
  530. Donaldson C.W, et al. Thrombectomy using suction filtration and veno-venous bypass: single center experience with a novel device. Catheter Cardiovasc Interv. 2015;86(2):81-87. 
  531. Ray C.E., Prochazka A. The need for anticoagulation following inferior vena cava filter placement: systematic review. Cardiovasc Intervent Radiol. 2008;31(2):316-324. 
  532. Langham MR, Hoffman MJ, Greenfield LJ. Effect of anticoagulation on the lysis of filter entrapped thromboembolism in dogs. J Surg Res. 1985; 38(4):391-399. 
  533. Ageno W, et al. The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. Thromb Haemost. 2013;11(8):1597-1602.
  534. Egermayer P. The effects of heparin and oral anticoagulants on thrombus propagation and prevention of the postphlebitic syndrome: a critical review of the literature. Prog Cardiovasc Dis. 2001;44(1):69-80. 
  535. Gautam G, Sebastian T, Klok FA. How to Differentiate Recurrent Deep Vein Thrombosis from Postthrombotic Syndrome. Hamostaseologie. 2020; 40(3):280-291. 
  536. van Dam LF, et al. Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis. Blood. 2020;135(16):1377-1385.
  537. Kyrle PA. How I treat recurrent deep-vein thrombosis. Blood. 2016;127(6): 696-702. 
  538. van Dam LF, Gautam G, Dronkers CEA. Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis. Thromb Haemost. 2020;18(9):2341-2348.
  539. Hassen S, et al. High percentage of non-diagnostic compression ultrasonography results and the diagnosis of ipsilateral recurrent proximal deep vein thrombosis: a rebuttal. Thromb Haemost. 2011;9(2):414-416; author reply 417-418. 
  540. Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood. 2017;129(25):3285-3293.
  541. Luk C, et al. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med. 2001;111(4):270-273. 
  542. Carrier M, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. Thromb Haemost. 2009;7(5):760-765. 
  543. Joseph L, et al. Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia. Thromb Haemost. 2014;12(7): 1044-1053.
  544. van Es N, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968-1975.
  545. Chechulova AV, et al. Bleeding in elderly and senile patients with deep vein thrombosis on anticoagulant therapy. Flebologiya. 2021;15(3):170-176. (In Russ.).
  546. Pengo V., Denas G. Optimizing quality care for the oral vitamin K antagonists (VKAs). Hematology. 2018;2018(1):332-338. 
  547. Palareti G, Cosmi B. Bleeding with anticoagulation therapy — who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102(2): 268-278. 
  548. Sarode R, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243.
  549. Chai-Adisaksopha C, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016;116(5):879-890. 
  550. Steiner T, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566-573. 
  551. Pollack C. V et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med. 2017;377(5):431-441. 
  552. Chaudhary R, et al. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis. JAMA Netw. 2022;5(11):e2240145.
  553. Piran S, et al. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv. 2019;3(2):158-167. 
  554. Connolly SJ, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326-1335.
  555. Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasa. 2001;30(3):195-204. 
  556. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med. 2004; 164(18):1961-1964.
  557. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715.
  558. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644-1649.
  559. Ivascu NS, et al. Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists. J Cardiothorac Vasc Anesth. 2019; 33(2):511-520. 
  560. Warkentin TE, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
  561. Warkentin TE, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):340-380. 
  562. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292.
  563. Salter BS, et al. Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. J Am Coll Cardiol. 2016;67(21):2519-2532.
  564. Sun X, et al. Heparin-Induced Thrombocytopenia in Contemporary Cardiac Surgical Practice and Experience With a Protocol for Early Identification. Am J Cardiol. 2016;117(2):305-309. 
  565. Cuker A. Management of the multiple phases of heparin-induced thrombocytopenia. Thromb Haemost. 2016;116(5):835-842. 
  566. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101(5):502-507. 
  567. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121(4):535-555. 
  568. Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost. 2011;106(6):993-994. 
  569. Greinacher A, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96(3):846-851. 
  570. Linkins L, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials. Res Pract Thromb Haemost. 2018;2(4):678-683. 
  571. Barlow A, et al. Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia. Pharmacotherapy. 2019; 39(8):837-853. 
  572. Tran PN, Tran M-H. Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia. Clin Appl Thromb. 2018;24(2):201-209. 
  573. Linkins LA, et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. Thromb Haemost. 2016;14(6):1206-1210.
  574. Warkentin TE, Pai M, Linkins L-A. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104-1113.
  575. Jung M, et al. Safety of IVC Filters with Heparin-Induced Thrombocytopenia: A Retrospecive Study. Blood. 2011;118(21):2225-2225.
  576. Hong AP, et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003;101(8):3049-3051.
  577. Warkentin TE, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127(9): 804-812. 
  578. Srinivasan AF, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164(1):66-70. 
  579. Goel R, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9): 1470-1476.
  580. ROAG. Venoznye oslozhneniya vo vremya beremennosti i poslerodovom periode. Akusherskaya tromboemboliya. Klinicheskie rekomendacii [Electronic resource]. https://cr.minzdrav.gov.ru/schema/723_1.
  581. Flebit i tromboflebit poverhnostnyh sosudov. Klinicheskie rekomendacii [Electronic resource]. 2021. cr.minzdrav.gov.ru/recomend/668_1.
  582. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet Gynecol. 2018;132(1):1-17. 
  583. RCOG. Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk. RCOG Green-top Guideline No. 37a [Electronic resource]. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/
  584. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstet Gynecol. 2018;132(1):18-34. 
  585. Bates SM, et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. Thromb Thrombolysis. 2016;41(1):92-128. 
  586. Middeldorp S. Is thrombophilia testing useful? Hematol Am Soc Hematol. 2011;2011(1):150-155. 
  587. Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol. 2008;198(2):233.e1-7. 
  588. RCOG. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management. RCOG Green-top Guideline No. 37b [Electronic resource]. 2015. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37b/
  589. Bates SM, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 sSuppl):691-736. 
  590. Cohen SL, et al. Comparison of international societal guidelines for the diagnosis of suspected pulmonary embolism during pregnancy. Lancet. Haematol. 2020;7(3):247-258. 
  591. Mallick S, Petkova D. Investigating suspected pulmonary embolism during pregnancy. Respir Med. 2006;100(10):1682-1687.
  592. Wan T, et al. Guidance for the diagnosis of pulmonary embolism during pregnancy: Consensus and controversies. Thromb Res. 2017;157:23-28. 
  593. Righini M, et al. Diagnosis of Pulmonary Embolism During Pregnancy: A Multicenter Prospective Management Outcome Study. Ann Intern Med. 2018;169(11):766-773. 
  594. van der Pol LM, et al. Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. N Engl J Med. 2019;380(12):1139-1149.
  595. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401-407. 
  596. Sagaram D, et al. Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions. Am J Perinatol. 2018;35(9):898-903. 
  597. To MS, Hunt BJ, Nelson-Piercy C. A negative D-dimer does not exclude venous thromboembolism (VTE) in pregnancy. J Obstet Gynaecol. 2008;28(2):222-223. 

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.